Cdp Equity invests approximately $1 billion in Angelini Pharma, acquiring a 23.5% stake through an increase of capital. The holding of investment by Cassa Depositi e Prestiti enters the most significant step in the international growth of the Italian group: completing the acquisition of Catalyst Pharmaceuticals, an active player in neurosciences and rare diseases valued at $4.1 billion (approximately $3.5 billion euros). This transaction adds to the size of the company and modifies its geographic baricenter, particularly strengthening its presence in the US market and ambition to operate globally on Brain Health and Rare Diseases segments.

With the completion of this operation, Catalyst joins the international platform of Angelini Pharma. Catalyst was quoted on Nasdaq; its shares are withdrawn from the list and recognized as cash compensation for shareholders of $31.50 per share. Closing concludes so the autonomous experience of Catalyst in Borsa and opens up the phase of its industrial and commercial integration into the Italian group.

Catalyst brings innovative drugs portfolio, specialized expertise and sales network already developed on the American market. For Angelini Pharma, these activities allow immediate access to products and infrastructure that would have required longer times to be built internally. The meaning of this acquisition goes beyond financial value but also concerns operational capabilities already available.

The operation concentrates the international strategy of the group on Neurosciences and Rare Diseases. Presence of Catalyst in the US market should enable Angelini Pharma to expand distribution and integrate respective specializations. Sources describe this passage as a decisive reinforcement in the American market without however providing estimates on revenues, economic synergies or time needed to complete integration.

Increase of capital subscribed by Cdp Equity supports financially this change of scale. Quota communicated is 23.5% even if title of Corriere della Sera indicates it rounded at 23%. No substantial divergence between sources on investment amount (approximately $1 billion) nor link with new partner and expansion path of Angelini Pharma emerges.

Structure financing partakes Blackstone funds managed, an investment of approximately $1 billion in privileged shares. According to FIRSTonline, this intervention is subordinate to usual authorizing regulations. New capital conferred by Cdp Equity and expected contribution through privileged instruments support acquisition valued at $3.5 billion euros.

For Cdp Equity, this operation belongs to activity supporting Italian strategic companies considered growth-oriented on international markets. Administrator delegate Fabio Barchiesi defined investment as concrete example of role played by society towards National System. Intervention thus brings investor recognizable Cassa Depositi e Prestiti into capital of pharmaceutical company italian in phase of global expansion.

Principal industrial effect is enlargement of presence of Angelini Pharma in US market. Catalyst offers commercial structure already operational and activities focused on same therapeutic areas that group Italian intends growing up. Acquisition allows combining portfolio and expertise of American society with international platform of Angelini Pharma reducing times necessary for building comparable position in the American market.

Next stage will concern integration of Catalyst, organization common portfolio and effects of new structure azionary of Angelini Pharma. Remainder to complete authorization process indicated for investment funds managed by Blackstone. Sources do not provide calendar or quantify results economic attested: these elements should clarify impact effect of this operation on growth path of the group.